Mersana Therapeutics, Inc. (MRSN) analyst actions
Rating and price-target actions on MRSN in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the MRSN overview →
1 measured MRSN analyst action event.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Mersana Therapeutics Announces Positive Initial Clinical Data from Phase 1 Clinical Trial of Emiltatug Ledadotin (XMT-1660); Initiation of Expansion in Triple Negative Breast Cancer | Press release | -0.91% | -32.08% |
Keep exploring
More MRSN: earnings → · SEC filings → · MRSN overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| DOVA PHARMACEUTICALS (DOVA) | 251 | -0.10% | 46% |
| Krystal Biotech, Inc. (KRYS) | 251 | +0.05% | 52% |
| Soligenix, Inc. (SNGX) | 251 | -0.71% | 35% |
| Co-Diagnostics, Inc. (CODX) | 250 | 0.00% | 46% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.